



European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

Declaration on compliance with the ENCePP Code of Conduct for ENCePP Seal studies¹

The (primary) lead investigator and a person authorised to sign on behalf of the coordinating study entity hereby declare for the purpose of conducting the study <include here study name and identifier/reg.no.> CAMERRA study / ENCEPP EUPAS21285

- to follow the rules and principles for the independent and transparent conduct of pharmacoepidemiological and pharmacovigilance studies of the current version of the ENCePP Code of Conduct²;
- to inform the ENCePP Secretariat, without delay, of any change or decision to change that constitutes a deviation from the provisions of this Code.

It is of note that the (primary) lead investigator and the person authorised to sign on behalf of the coordinating study entity may be identical.

Name of (primary) lead investigator:

Dr Patrick BLIN

Date: 07/03/2018 (dd/mm/yyyy)

Stamp (if applicable) and signature:

Name of the coordinating study entity: Bordeaux PharmacoEpi

Address:

University of Bordeaux Department of Pharmacology Case 41 146 rue Léo Saignat 33076 Bordeaux cedex - France

Name of person authorised to sign on behalf of the coordinati tity [if different from (primary) lead investigator]:

Pr Nicholas Moore

Date: 07/03/2018 (dd/mm/yyyy)

Stamp (if applicable) and signature:

The (primary) lead investigator should also complete, sign and date the Checklist of the ENCePP Code of Conduct for ENCePP Seal studies.

Reset Form

Complete the declaration on screen, then print, stamp (if applicable) and sign.